Protocol To Evaluate Patient Measurements After Ultrasonic Treatment
Protocol To Evaluate Patient Measurements After Ultrasonic Treatment.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10016
- Laser & Skin Surgery Center of New York
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Healthy Female between 20 and 50 years of age, inclusive, on the day of enrolment.
- Has a BMI between 20 and 30 kg/m2.
- Is to be treated in the posterior thigh / saddlebag area using the MC1.
- Has never been treated with the MC1 before.
- Females who are post menopausal or using a medically acceptable form of birth control prior to study enrollment and during the course of the study. (i.e., condoms with spermicide, oral contraceptives contraceptive implants etc.)
Exclusion Criteria:
- Subject is lactating, has a positive pregnancy test within 7 days of planned study procedure (for female subjects of child-bearing potential), or intends to become pregnant during the study.
- Currently enrolled in another device or drug study that has not completed the required follow-up period, or has completed all other study-required follow-up less than 30 days before enrolment in this study.
- Keloid scars, hypertorphic scars or a history of abnormal healing.
- Any known bruising disorder, anticoagulative / thromboembolic condition , hemorrhagic (bleeding) status or use of anti coagulants.
- Tissue ischemia in the area to be treated.
- Suffering from concurrent conditions such as liver or kidney disorders, Hypertension or abnormally high blood pressure.
- High cholesterol and/or diabetes.
- Active collagen vascular disease (e.g. fibromyalgia, panniculitis, lupus etc.).
- Epilepsy.
- Tuberculosis.
- Auxiliary electric organs (such as pacemakers), metal or myoelectric prosthesis.
- Suffering from Endocrine syndromes or thyroid hyperfunction.
- Active skin infection, any infection in the treated area within the last 30 days or skin disease in the area to be treated (e.g. eczema, psoriasis, urticaria, dermographism).
- Bone, muscle or joint disease, dysfunction or healing in the area to be treated.
- Malignancy in the area to be treated.
- Laminectomy in the area to be treated.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
MC1 Subjects
|
Use of the VASERShape MC1 device as part of routine practice
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
Other Study ID Numbers
- SST2011-2
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.